Since its emergence, CRISPR technology has brought a tremendous leap forward in the biopharmaceutical industry. In collaboration with ViaCyte, CRISPR Therapeutics has developed two drug candidates, VCTX210 and VCTX211, both of which are gene-edited, allogeneic, stem cell-derived candidates for the treatment of type 1 diabetes. By transplanting pancreatic cells differentiated from stem cells, these therapies […]